Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
15 studies found for:    "Lymphoma AIDSrelated"
Show Display Options
Rank Status Study
1 Recruiting High-Dose Chemotherapy With Transplantation of Gene-Modified Stem Cells for High-Risk AIDS-Related Lymphoma
Conditions: AIDS-Related Lymphoma;   HIV Infections
Intervention: Procedure: PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)
2 Not yet recruiting Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I AIDS-related Lymphoma;   Stage II AIDS-related Lymphoma;   Stage III AIDS-related Lymphoma;   Stage IV AIDS-related Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: carmustine;   Drug: cytarabine;   Drug: melphalan;   Drug: etoposide;   Drug: O6-benzylguanine;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
3 Not yet recruiting Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
Conditions: AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Stage III AIDS-related Lymphoma;   Stage IV AIDS-related Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: lomustine;   Drug: etoposide;   Drug: procarbazine hydrochloride;   Other: laboratory biomarker analysis
4 Terminated Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma
Condition: AIDS Related Lymphoma
Interventions: Drug: rituximab;   Drug: CHOP
5 Completed EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
Condition: AIDS Related Lymphoma
Interventions: Biological: Filgrastim;   Biological: Rituximab;   Drug: EPOCH
6 Withdrawn Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Conditions: AIDS-related Lymphoma;   Adult Non-Hodgkin's Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: cisplatin;   Drug: cytarabine;   Drug: etoposide;   Drug: methylprednisolone;   Drug: rituximab;   Drug: yttrium Y 90 ibritumomab tiuxetan;   Procedure: antibody therapy;   Procedure: biological  therapy;   Procedure: chemotherapy;   Procedure: monoclonal antibody therapy;   Procedure: radiation therapy;   Procedure: radioimmunotherapy;   Procedure: radioisotope therapy
7 Completed Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
Condition: Lymphoma
Interventions: Biological: Bleomycin Sulfate;   Biological: Filgrastim;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride (DOX);   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Ifosfamide;   Drug: Leucovorin calcium;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pentamidine;   Drug: Prednisone;   Drug: Trimethoprim-Sulfamethoxazole;   Drug: Vincristine Sulfate;   Drug: Zidovudine (AZT);   Radiation: Radiation Therapy
8 Completed Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: peripheral blood stem cell transplantation
9 Withdrawn Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma
Condition: Lymphoma
Interventions: Biological: anti-thymocyte globulin;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
10 Completed SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: prednisone;   Drug: trimethoprim-sulfamethoxazole;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Drug: Intrathecal cytarabine
11 Completed Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: methotrexate;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
12 Active, not recruiting Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
Condition: Lymphoma
Interventions: Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: autologous hematopoietic stem cell transplantation
13 Completed Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
Condition: Lymphoma
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: lomustine;   Drug: procarbazine hydrochloride;   Radiation: radiation therapy
14 Unknown  Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
Conditions: Bladder Cancer;   Brain and Central Nervous System Tumors;   Esophageal Cancer;   Intraocular Melanoma;   Kidney Cancer;   Lymphoma;   Melanoma (Skin);   Pancreatic Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration
15 Withdrawn Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
Conditions: Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Nausea and Vomiting;   Solid Tumor
Interventions: Drug: aprepitant;   Drug: ondansetron hydrochloride

Indicates status has not been verified in more than two years